AdAlta (ASX:1AD) Short-Term Capital Lease Obligation : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Short-Term Capital Lease Obligation?

AdAlta's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil.

AdAlta Short-Term Capital Lease Obligation Historical Data

The historical data trend for AdAlta's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Short-Term Capital Lease Obligation Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.12

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial											-	-	-	-	0.12

AdAlta Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

AdAlta Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of AdAlta's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

AdAlta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta Headlines

No Headlines